CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack-Reference-Cited by-同舟云学术

CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack

Published:2010-10-14 Issue:1 Volume:18 Page:62-72
ISSN:0969-7128
Container-title:Gene Therapy
language:en
Short-container-title:Gene Ther

Author:

Chmielewski M,Hombach A A,Abken H

Publisher

Springer Science and Business Media LLC

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/gt2010127.pdf

Reference38 articles.

1. Eshhar Z . The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 2008; 181: 329–342.

2. Brocker T, Karjalainen K . Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med 1995; 181: 1653–1659.

3. Brocker T . Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 2000; 96: 1999–2001.

4. Thislethwaite F, Mansoor W, Gilham DE, Hawkins RE . Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy. Curr Opin Mol Ther 2005; 7: 48–55.

5. Hombach A, Abken H . Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy. Cancer Immunol Immunther 2007; 56: 731–737.

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitory CARs fail to protect from immediate T cell cytotoxicity;Molecular Therapy;2024-04

2. Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells;2024-02-23

3. Standardization of flow cytometric detection of antigen expression;Cytometry Part B: Clinical Cytometry;2024-01

4. Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells;Immunotherapy Advances;2024-01-01

5. Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes;Frontiers in Immunology;2023-11-07